Mahendra rao
Chief Scientific Officer Vita Therapeutics
Seminars
Wednesday 9th September 2026
Implementing GMP‑Compatible Gene Editing Strategies to Enable Scalable iPSC‑Derived Cell Manufacturing
1:40 pm
- Translating complex immune‑evasion gene‑editing strategies into manufacturable iPSC platforms, without committing to multiple costly master cell lines
- Designing flexible, staged CRISPR editing and evaluation workflows to balance product customization, speed, and control in GMP manufacturing
- Navigating real‑world constraints in gene edited iPSC manufacturing, including CRISPR selection, IP and licensing considerations, and CDMO readiness
